Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
Celcuity (Nasdaq: CELC) reported Q1 2026 results and key updates for gedatolisib in HR+/HER2- advanced breast cancer.
The Phase 3 VIKTORIA-1 trial met its primary endpoint with statistically significant, clinically meaningful PFS benefit in PIK3CA mutant patients; an NDA has Priority Review with a July 17, 2026 PDUFA date. Cash was $387.1 million, expected to fund operations through 2027.
Positive
- VIKTORIA-1 Phase 3 met primary PFS endpoint in PIK3CA mutant cohort
- Both gedatolisib triplet and doublet showed statistically significant PFS improvement vs alpelisib regimens
- FDA granted Priority Review to gedatolisib NDA; PDUFA date July 17, 2026
- VIKTORIA-2 expanded with second Phase 3 study in first-line endocrine-sensitive HR+/HER2- disease
- First patent application filed for subcutaneous gedatolisib formulation
- Cash, cash equivalents and short-term investments of $387.1 million; funding expected through 2027
Negative
- Net loss increased to $52.8 million from $37.0 million year over year
- Non-GAAP adjusted net loss rose to $46.8 million from $34.7 million
- Total operating expenses grew to $50.5 million from $36.1 million
- SG&A expenses nearly tripled to $17.4 million from $6.3 million
- Net cash used in operating activities rose to $55.1 million from $35.9 million
News Market Reaction – CELC
In the May 15 session, CELC gained 2.20%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 25 | FY25 earnings update | Positive | +4.2% | FY25 results plus NDA Priority Review and strong VIKTORIA-1 PFS data. |
| Nov 12 | Q3 2025 earnings | Positive | +1.0% | Q3 2025 results and detailed PIK3CA WT VIKTORIA-1 Phase 3 efficacy data. |
| Aug 14 | Q2 2025 earnings | Positive | -0.2% | Q2 2025 results with breakthrough VIKTORIA-1 data and $286.5M capital raise. |
| May 14 | Q1 2025 earnings | Neutral | -3.1% | Q1 2025 results and guidance on upcoming VIKTORIA-1 and VIKTORIA-2 milestones. |
| Mar 31 | FY24 earnings update | Neutral | -8.1% | FY24 results with widening losses and timeline for key Phase 3 readouts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often pair widening losses and higher operating spend with positive gedatolisib milestones and generally modest share reactions.
Over the past five earnings-related announcements, Celcuity has consistently combined clinical progress for gedatolisib with rising operating expenses and net losses. Earlier updates highlighted VIKTORIA‑1 Phase 3 data, Priority Review, and a July 17, 2026 PDUFA date, while maintaining cash runways into 2026–2027. Reactions ranged from mild gains to small declines, and average move was -1.25%. Today’s Q1 2026 update fits this pattern: deeper losses and higher SG&A and R&D alongside pivotal trial success and commercial launch preparations.
Key Terms
progression-free survival medical
HR+/HER2- medical
PIK3CA medical
Phase 3 medical
subcutaneous injection medical
New Drug Application regulatory
supplemental New Drug Application regulatory
PDUFA regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented at the 2026 ASCO Annual Meeting
- Phase 3 VIKTORIA-2 trial expanded to include a second study evaluating gedatolisib as first-line treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer
- Development of a gedatolisib formulation for subcutaneous injection underway; first patent application submitted to the U.S. Patent and Trademark Office
- Management to host webcast and conference call today, May 14, 2026, at 4:30 p.m. EDT
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the first quarter ended March 31, 2026 and other recent business developments.
“With positive results in both cohorts of the pivotal VIKTORIA-1 study, we believe gedatolisib regimens have the potential to advance the standard of care in the second-line setting for a significant number of patients with HR+/HER2- advanced breast cancer, regardless of PIK3CA status,” said Brian Sullivan, CEO and co-founder of Celcuity. “We are on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026, and we look forward to bringing this important therapy to physicians treating patients with advanced breast cancer.”
Mr. Sullivan added, “Our positive Phase 3 results, combined with our promising Phase 1b clinical trial results in treatment-naive late-stage patients, provide a strong scientific rationale to evaluate gedatolisib combinations as first-line therapy. By expanding our VIKTORIA-2 study to enable evaluation of treatment-naive patients who have endocrine-sensitive breast cancer, we are positioning gedatolisib regimens to potentially be available for nearly all patients in the first-line setting, irrespective of their endocrine sensitivity or PIK3CA status.”
First Quarter 2026 Business Highlights and Other Recent Developments
- Celcuity reported positive topline results from the PIK3CA mutant-type (“MT”) cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) (“HR+/HER2-”), PIK3CA MT locally advanced or metastatic breast cancer (“ABC”).
- The primary efficacy analysis of gedatolisib combined with fulvestrant and palbociclib (the “gedatolisib triplet”) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) compared with alpelisib, a PI3Kα inhibitor, and fulvestrant.
- The secondary endpoint comparing gedatolisib in combination with fulvestrant (the “gedatolisib doublet”) versus alpelisib plus fulvestrant, which was not part of the primary efficacy analysis in the hierarchical order, also demonstrated a statistically significant and clinically meaningful improvement in PFS.
- Both gedatolisib regimens were generally well tolerated, with manageable safety profiles, and no new safety signals.
- Detailed data for the gedatolisib triplet and doublet regimens will be presented in a late-breaking abstract (“LBA”) oral session on June 2, 2026, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois.
- Celcuity intends to submit these data to the FDA in the third quarter as a supplemental New Drug Application (“sNDA”) and to submit VIKTORIA-1 data to other regulatory authorities outside the U.S. following the sNDA submission.
- The Phase 3 VIKTORIA-2 clinical trial now includes two studies, Study 1 and Study 2, each with independent statistical analysis plans that include primary endpoints for their respective intent-to-treat populations. Study 1, which is ongoing, is evaluating the efficacy and safety of gedatolisib in combination with palbociclib and fulvestrant in approximately 440 patients with endocrine-resistant HR+/HER2- ABC. Study 2, which was added in conjunction with a VIKTORIA-2 protocol amendment, is evaluating the efficacy and safety of gedatolisib in combination with palbociclib and letrozole in approximately 740 patients with treatment-naive endocrine-sensitive HR+/HER2- ABC. Eligible patients include those whose cancer relapsed or progressed 12 months or more after completion of adjuvant endocrine therapy, or those with de novo metastatic disease without prior endocrine therapy exposure. Approximately 60,000 adults are newly diagnosed each year in the United States with endocrine-sensitive HR+/HER2- ABC.1
- To support its long-term lifecycle development plan, Celcuity submitted its first patent application to the United States Patent and Trademark Office (“USPTO”) for a subcutaneous formulation of gedatolisib that would enable a patient to receive gedatolisib as an injection as an alternative to an infusion. Development of the subcutaneous gedatolisib formulation is ongoing with the goal of demonstrating clinical equivalence to the current intravenous formulation of gedatolisib. The subcutaneous formulation is aimed to support potential future indications for gedatolisib regimens that may result in duration of treatment periods greater than several years.
- In January 2026, the FDA accepted the submission of Celcuity’s New Drug Application (“NDA”) for gedatolisib in HR+/HER2- PIK3CA wild-type (“WT”) ABC. The FDA granted Priority Review and assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026.
First Quarter 2026 Financial Results
Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2026, compared to the first quarter ended March 31, 2025.
Net loss for the first quarter of 2026 was
Total operating expenses were
Research and development (“R&D”) expenses were
Selling, general and administrative (“SG&A”) expenses were
Net cash used in operating activities for the first quarter of 2026 was
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865.
A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR (“PAM”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, has reported detailed results for Study 1, which evaluated patients with PIK3CA WT tumors, and announced topline results for Study 2, which evaluated patients with PIK3CA MT tumors. Our Phase 3 clinical trial, VIKTORIA-2, is ongoing and incorporates two independent studies, Study 1 and Study 2, evaluating two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib combined with palbociclib and fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib combined with palbociclib and letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the potential therapeutic benefits of gedatolisib; the size, design and timing of our clinical trials; our interpretation of clinical trial data; the status and timing of the FDA’s review of our NDA for gedatolisib, including the PDUFA goal date assigned by the FDA; the ability of our data to support the filing of an sNDA with the FDA and comparable filings with other regulatory authorities outside the U.S.; our intent to present data at the 2026 ASCO Annual Meeting; the market opportunity for gedatolisib; our expectations regarding the timing of and our ability to obtain FDA approval to commercialize gedatolisib; our strategy, marketing and commercialization plans, including the benefits of strategic decisions regarding studies and trials; other expectations with respect to gedatolisib, including subcutaneous formulations to support potential future indications for gedatolisib regimens; our anticipated use of cash; and the strength of our balance sheet. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” "confidence," "encouraged," “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that our topline clinical results are based on an ongoing analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial; unforeseen delays in our clinical trials or the FDA’s review of our NDA for gedatolisib; our ability to obtain and maintain regulatory approvals to commercialize gedatolisib, and the market acceptance of gedatolisib; the development of therapies and tools competitive with gedatolisib; and our ability to access capital upon favorable terms. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 26, 2026, as such risks may be updated in our subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
References:
1. Internal estimates using data from National Cancer Institute, SEER, 2024; Pan, H, NEJM, 2017;377:1836-46; Dowsett, M 2009; Salvo, E. M. et al. 2021
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
| Celcuity Inc. | |||||||||
| Condensed Balance Sheets | |||||||||
| (in thousands) | |||||||||
| March 31, 2026 | December 31, 2025 | ||||||||
| (unaudited) | |||||||||
| Assets | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 145,191 | $ | 165,703 | |||||
| Investments | 241,873 | 275,794 | |||||||
| Other current assets | 21,865 | 24,162 | |||||||
| Total current assets | 408,929 | 465,659 | |||||||
| Property and equipment, net | 619 | 499 | |||||||
| Operating lease right-of-use assets | 13 | 51 | |||||||
| Other non-current assets | 603 | 349 | |||||||
| Total assets | $ | 410,164 | $ | 466,558 | |||||
| Liabilities and stockholders' equity | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 10,454 | $ | 6,407 | |||||
| Accrued expenses | 22,744 | 37,691 | |||||||
| Operating lease liabilities, current | 13 | 54 | |||||||
| Total current liabilities | 33,211 | 44,152 | |||||||
| Convertible notes | 195,566 | 195,324 | |||||||
| Note payable | 127,862 | 126,527 | |||||||
| Total liabilities | 356,639 | 366,003 | |||||||
| Total stockholders' equity | 53,525 | 100,555 | |||||||
| Total liabilities and stockholders' equity | $ | 410,164 | $ | 466,558 | |||||
| Celcuity Inc. | |||||||
| Condensed Statements of Operations | |||||||
| (unaudited) | |||||||
| (in thousands, except share and per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Operating expenses: | |||||||
| Research and development (1) | $ | 33,063 | $ | 29,759 | |||
| Selling, general and administrative (1) | 17,444 | 6,374 | |||||
| Total operating expenses | 50,507 | 36,133 | |||||
| Loss from operations | (50,507 | ) | (36,133 | ) | |||
| Other (expense) income: | |||||||
| Interest expense | (6,085 | ) | (3,183 | ) | |||
| Interest income | 3,751 | 2,319 | |||||
| Other (expense) income, net | (2,334 | ) | (864 | ) | |||
| Net loss before income taxes | (52,841 | ) | (36,997 | ) | |||
| Income taxes | — | — | |||||
| Net loss | $ | (52,841 | ) | $ | (36,997 | ) | |
| Net loss per share, basic and diluted | $ | (0.97 | ) | $ | (0.86 | ) | |
| Weighted average common shares outstanding, basic and diluted | 54,462,826 | 43,052,757 | |||||
(1) Certain prior period amounts have been reclassified from research and development expenses to selling, general and administrative expenses to conform to the current period presentation.
Cautionary Statement Regarding Non-GAAP Financial Measures
This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense, non-cash interest expense, and non-cash interest income from net loss and net loss per share. Management excludes these items because they do not impact Celcuity’s cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management’s method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity’s performance or as a measure of liquidity and cash flows.
| Celcuity Inc. | ||||||||
| Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and | ||||||||
| GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share | ||||||||
| (unaudited) | ||||||||
| (in thousands, except share and per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| GAAP net loss | $ | (52,841 | ) | $ | (36,997 | ) | ||
| Adjustments to net loss: | ||||||||
| Stock-based compensation | ||||||||
| Research and development (1), (2) | 2,112 | 1,164 | ||||||
| Selling, general and administrative (1), (3) | 3,213 | 1,280 | ||||||
| Non-cash interest expense (4) | 1,577 | 800 | ||||||
| Non-cash interest income (5) | (883 | ) | (946 | ) | ||||
| Non-GAAP adjusted net loss | $ | (46,822 | ) | $ | (34,699 | ) | ||
| GAAP net loss per share - basic and diluted | $ | (0.97 | ) | $ | (0.86 | ) | ||
| Adjustments to net loss: | ||||||||
| Stock-based compensation | ||||||||
| Research and development | 0.04 | 0.02 | ||||||
| Selling, general and administrative | 0.06 | 0.03 | ||||||
| Non-cash interest expense | 0.03 | 0.02 | ||||||
| Non-cash interest income | (0.02 | ) | (0.02 | ) | ||||
| Non-GAAP adjusted net loss per share - basic and diluted | $ | (0.86 | ) | $ | (0.81 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 54,462,826 | 43,052,757 | ||||||
(1) Certain prior period amounts have been reclassified from research and development expenses to selling, general and administrative expenses to conform to the current period presentation.
(2) To reflect a non-cash adjustment to operating expenses for research and development stock-based compensation.
(3) To reflect a non-cash adjustment to operating expenses for selling, general and administrative stock-based compensation.
(4) To reflect a non-cash adjustment to other expense for amortization of debt issuance costs and discount and payment-in-kind interest related to the issuance of the convertible notes and note payable.
(5) To reflect a non-cash adjustment to other income for accretion on investments and change in accrued interest income.
